Will This Billion-Dollar Acquisition Be a Smart Move for Merck?
Merck recently completed its acquisition of a California-based biotech company.
Source: fool.com
📰 Imago Bioscience News
Imago Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Imago Bioscience. Real-time updates on events, politics, business and more.
Merck to buy Xeraya-backed biopharma firm Imago BioSciences for $1.35b
The deal marks Malaysia-based Xeraya's exit from the biopharma firm.
Source: dealstreetasia.com
Merck acquires Imago BioSciences drug developer for $1.35B
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
Source: econotimes.com
This biopharma stock more than doubled on Monday: find out more
Merck & Co Inc to buy Imago Biosciences in a $1.35 billion deal. Imago Biosciences stock opened more than 100% up on Monday.
Source: invezz.com
Making immunotherapy more effective against small cell lung cancer
Fred Hutchinson Cancer Center lung cancer scientists open a human trial after preclinical work shows that making small cell lung cancer more visible to immune cells can make the tumors more responsive to immunotherapy.
New York United States Rafael Santana Davila University Of Washington Hutch Specialized Program Of Research Excellence Cancer Act
Source: fredhutch.org
Zacks: Brokerages Anticipate Imago BioSciences Inc (NASDAQ:IMGO) Will Post Earnings of -$0.39 Per Share
Equities research analysts forecast that Imago BioSciences Inc (NASDAQ:IMGO – Get Rating) will post ($0.39) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Imago BioSciences’ earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.40). The business is expected to report its […]
Laurag Eichorn Jennifer Peppe Jefferies Financial Group Emerald Mutual Fund Advisers Imago Biosciences Inc Zacks Investment Research
Source: etfdailynews.com